Research library

A

grade

The paper suggests that semaglutide represents a significant advancement in obesity treatment, but specific outcomes are not detailed.

–14.9% weight loss vs placebo at 68 wk, n=1961, p<0.001

summary

A

grade

Cagrisema may lead to greater weight loss compared to semaglutide alone, but the clinical relevance of cagrilintide's effects compared to semaglutide/liraglutide is uncertain.

MD -9.07% weight loss at 20-32 weeks with Cagrisema vs semaglutide, 95%CI: -11.91, -6.23; p < 0.00001; I2 = 96%

summary

B

grade

Most studies on anti-obesity medications in Arab countries are observational, with a focus on older drugs like liraglutide, and gastrointestinal side effects were reported in 32.2% of patients.

32.2% of patients reported gastrointestinal side effects.

summary

D

grade

Semaglutide has shown promise in managing type 2 diabetes and obesity, with significant weight loss and glycemic control observed in clinical trials. However, further research is needed to confirm these findings across broader populations.

Not reported in abstract.

summary

A

grade

High dose CagriSema led to a significant weight loss of -17.18% compared to placebo, but findings are based on low-certainty data and require further validation.

-17.18% body weight change with high dose CagriSema vs placebo

summary

C

grade

Not reported in abstract.

Cagrilintide (AM833) had an EC50 value of 0.5 nM for receptor activation.

summary